Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6397-6401

  Kara, Oguz ^a   Duman, Berna Bozkurt ^a   Kara, Banu ^b   Erdogan, Seyda ^a   Parsak, Cem Kaan ^a   Sakman, Gürhan ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bevacizumab; Colorectal cancer; HER2 neu; p53; PTEN; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COLORECTAL TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84877049200     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6397     Document Type: Article

References (27)

1. Ahwon L, Woo CP, Hyeon WY, et al (2007). Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol, 37, 708-14.
2. Asghar U, Hawkes E, Cunningham D (2010). Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer, 9, 274-81.
3. Cacheux W, Le Tourneau C, Baranger B, Mignot L, Mariani P (2011). Targeted biotherapy in metastatic colorectal carcinoma: Current practice. J Visc Surg, 148, 12-8.
4. Christos NP, Christopher JL (2004). Bortezomib as a potential treatment for prostate cancer. Cancer Res, 64, 5036-43.
5. Chua W, Moore MM, Charles KA, Clarke SJ (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Curr Opin Mol Ther, 11, 611-22.
6. Colakoglu T, Yildirim S, Kayaselcuk F, et al (2008). Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg, 195, 719-25.
7. Des GG, Uzzan B, Nicolas P, et al (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer, 94, 1823-32.
8. Hawkes E, Cunningham D (2010). Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol, 28, 529-31.
9. Herreros-Villanueva M, Rodrigo M, Claver M, et al (2011). KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep, 38, 1315-20.
10. Jalbǎ CS, Jalbǎ BA, Nicula C, et al (2011). Clinical relevance of vascular endothelial growth factor-A in colorectal cancer. Rom J Morphol Embryol, 52, 775-81.
11. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
12. Klos KS, Wyszomierski SL, Sun M, et al (2006). ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/ p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res, 66, 2028-37.
13. Li Q, Wang D, Li J, Chen P (2011). Clinicopathologic and prognostic significance of HER-2/neu and VEGF expression in colon carcinoma. BMC Cancer, 11, 277.
14. Lohrum MA, Woods DB, Ludwig RL, Bálint E, Vousden KH (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol, 21, 8521-32.
15. Longo R, Gasparini G (2007). Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol, 60, 151-70.
16. Munro AJ, Lain S, Lane DP (2005). p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer, 92, 434-44.
17. Murad JC, Ribeiro U Jr, Safatle-Ribero AV, et al (2007). Evaluation of moleculer markers in hepatic metastasis of colorectal adenocarcinoma. Hepatogastroenterology, 54, 1029-33.
18. Perrone G, Santini D, Verzì A, et al (2006). COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol, 59, 492-6.
19. Pohl M, Werner N, Munding J, et al (2011). Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol, 49, 1398-406.
20. Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar SM (2009). Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol, 4, 41.
21. Yang W, Klos K, Yang Y, et al (2002). ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer, 94, 2855-61.
22. Van CE, Köhne CH, Láng I, et al (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 29, 2011-9.
23. Wei Q, Shui Y, Zheng S, et al (2011). EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep, 25, 3-11.
24. Wong R, Cunningham D (2008). Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol, 26, 5668-70.
25. Yen L, Benlimame N, Nie ZR, et al (2002). Differential regulation of tumor angiogenesis by distinct ErbB homo-and heterodimers. Mol Biol Cell, 13, 4029-44.
26. Yen L, You XL, Al Moustafa AE, et al (2000). Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene, 19, 3460-9.
27. Zhou YJ, Xiong YX, Wu XT, et al (2004). Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol, 10, 3225-9.